Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of “Hold” by Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned an average rating of “Hold” from the nineteen ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.88.

Several research firms recently issued reports on SAGE. Canaccord Genuity Group dropped their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Wedbush reaffirmed a “neutral” rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research note on Monday, December 16th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Caligan Partners LP purchased a new position in Sage Therapeutics during the 4th quarter valued at about $16,575,000. Boothbay Fund Management LLC purchased a new position in Sage Therapeutics during the 4th quarter valued at about $7,540,000. State Street Corp increased its holdings in Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after purchasing an additional 451,377 shares during the period. Federated Hermes Inc. increased its holdings in Sage Therapeutics by 63.7% during the 4th quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company’s stock valued at $6,004,000 after purchasing an additional 430,432 shares during the period. Finally, Jane Street Group LLC increased its holdings in Sage Therapeutics by 103.1% during the 4th quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock valued at $2,509,000 after purchasing an additional 234,528 shares during the period. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $7.50 on Monday. The firm has a market capitalization of $461.11 million, a price-to-earnings ratio of -1.14 and a beta of 0.94. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $22.34. The stock has a fifty day moving average of $6.95 and a 200 day moving average of $6.75.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Equities analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.